FAMP, a Novel ApoA-I Mimetic Peptide, Suppresses Aortic Plaque Formation Through Promotion of Biological HDL Function in ApoE-Deficient Mice

Journal of the American Heart Association

Volumn 2, Issue 3, 2013, Pages

  Uehara, Yoshinari ^a   Ando, Setsuko ^a   Yahiro, Eiji ^a   Oniki, Kosuke ^a   Ayaori, Makoto ^b   Abe, Satomi ^a   Kawachi, Emi ^a   Zhang, Bo ^c   Shioi, Seijiro ^a   Tanigawa, Hiroyuki ^a   Imaizumi, Satoshi ^a   Miura, Shin Ichiro ^a   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^c FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apolipoproteins; ATP binding cassette transporters; HDL particle size; Peptides; pre HDL

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; C REACTIVE PROTEIN; CHOLESTEROL; FUKUOKA UNIVERSITY APOLIPOPROTEIN A1 MIMETIC PEPTIDE; FUKUOKA UNIVERSITY APOLIPOPROTEIN A1 MIMETIC PEPTIDE TYPE 5; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PEPTIDOMIMETIC AGENT; PRE BETA HIGH DENSITY LIPOPROTEIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG; ABC TRANSPORTER; APOLIPOPROTEIN; PEPTIDE;

AGAR GEL ELECTROPHORESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ATHEROSCLEROSIS; ARTICLE; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HYPERLIPOPROTEINEMIA TYPE 3; IN VITRO STUDY; LIPID DIET; LOW DRUG DOSE; MACROPHAGE; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTECTION; PROTEIN BLOOD LEVEL; SINGLE DRUG DOSE; SURFACE CHARGE; TREATMENT DURATION; ANIMAL; AORTIC DISEASES; C57BL MOUSE; DEFICIENCY; DRUG EFFECTS; PHYSIOLOGY; PLAQUE, ATHEROSCLEROTIC; TRANSPORT AT THE CELLULAR LEVEL; AORTA DISEASE; ATHEROSCLEROTIC PLAQUE; DRUG EFFECT; HDL PARTICLE SIZE; PRE-Β HDL;

ANIMALS; AORTIC DISEASES; APOLIPOPROTEINS E; BIOLOGICAL TRANSPORT; LIPOPROTEINS, HDL; MALE; MICE; MICE, INBRED C57BL; PLAQUE, ATHEROSCLEROTIC;

APOLIPOPROTEINS; ATP-BINDING CASSETTE TRANSPORTERS; HDL PARTICLE SIZE; PEPTIDES; PRE-Β HDL;

EID: 84886535631     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.113.000048     Document Type: Article

References (46)

1. von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 2001;21:13-27.
2. Yancey PG, Bortnick AE, Kellner-Weibel G, de la Llera-Moya M, Phillips MC, Rothblat GH. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol. 2003;23:712-719.
3. Davidson WS, Sparks DL, Lund-Katz S, Phillips MC. The molecular basis for the difference in charge between pre-beta- and alpha-migrating high density lipoproteins. J Biol Chem. 1994;269:8959-8965.
4. Kunitake ST, La Sala KJ, Kane JP. Apolipoprotein A-I-containing lipoproteins with pre-beta electrophoretic mobility. J Lipid Res. 1985;26:549-555.
5. Castro GR, Fielding CJ. Early incorporation of cell-derived cholesterol into prebeta- migrating high-density lipoprotein. Biochemistry. 1988;27:25-29.
6. Asztalos BF, Sloop CH, Wong L, Roheim PS. Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations. Biochim Biophys Acta. 1993;1169:291-300.
7. Barrans A, Jaspard B, Barbaras R, Chap H, Perret B, Collet X. Pre-beta HDL: structure and metabolism. Biochim Biophys Acta. 1996;1300:73-85.
8. Nanjee MN, Brinton EA. Very small apolipoprotein A-I-containing particles from human plasma: isolation and quantification by high-performance size-exclusion chromatography. Clin Chem. 2000;46:207-223.
9. Duriez P, Fruchart JC. High-density lipoprotein subclasses and apolipoprotein A-I. Clin Chim Acta. 1999;286:97-114.
10. Sparks DL, Frank PG, Braschi S, Neville TA, Marcel YL. Effect of apolipoprotein A-I lipidation on the formation and function of pre-beta and alpha-migrating LpA-I particles. Biochemistry. 1999;38:1727-1735.
11. de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol. 2010;30:796-801.
12. Hattori H, Kujiraoka T, Egashira T, Saito E, Fujioka T, Takahashi S, Ito M, Cooper JA, Stepanova IP, Nanjee MN, Miller NE. Association of coronary heart disease with pre-beta-HDL concentrations in Japanese men. Clin Chem. 2004;50:589-595.
13. Jafari M, Leaf DA, Macrae H, Kasem J, O'Conner P, Pullinger C, Malloy M, Kane JP. The effects of physical exercise on plasma prebeta-1 high-density lipoprotein. Metabolism. 2003;52:437-442.
14. Miida T, Sakai K, Ozaki K, Nakamura Y, Yamaguchi T, Tsuda T, Kashiwa T, Murakami T, Inano K, Okada M. Bezafibrate increases prebeta 1-HDL at the expense of HDL2b in hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 2000;20:2428-2433.
15. Sethi AA, Sampson M, Warnick R, Muniz N, Vaisman B, Nordestgaard BG, Tybjaerg-Hansen A, Remaley AT. High pre-beta1 HDL concentrations and low lecithin: cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol. Clin Chem. 2010;56:1128-1137.
16. Asztalos BF, Roheim PS, Milani RL, Lefevre M, McNamara JR, Horvath KV, Schaefer EJ. Distribution of apoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol. 2000;20:2670- 2676.
17. Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, Drobnik W, Barlage S, Buchler C, Porsch-Ozcurumez M, Kaminski WE, Hahmann HW, Oette K, Rothe G, Aslanidis C, Lackner KJ, Schmitz G. The gene encoding ATPbinding cassette transporter 1 is mutated in Tangier disease. Nat Genet. 1999;22:347-351.
18. Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, Yu L, Brewer C, Collins JA, Molhuizen HO, Loubser O, Ouelette BF, Fichter K, Ashbourne-Excoffon KJ, Sensen CW, Scherer S, Mott S, Denis M, Martindale D, Frohlich J, Morgan K, Koop B, Pimstone S, Kastelein JJ, Genest J Jr, Hayden MR. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet. 1999;22:336-345.
19. Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, Deleuze JF, Brewer HB, Duverger N, Denefle P, Assmann G. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet. 1999; 22:352-355.
20. Vedhachalam C, Duong PT, Nickel M, Nguyen D, Dhanasekaran P, Saito H, Rothblat GH, Lund-Katz S, Phillips MC. Mechanism of ATP-binding cassette transporter A1-mediated cellular lipid efflux to apolipoprotein A-I and formation of high density lipoprotein particles. J Biol Chem. 2007;282: 25123-25130.
21. Iwata A, Miura S, Zhang B, Imaizumi S, Uehara Y, Shiomi M, Saku K. Antiatherogenic effects of newly developed apolipoprotein A-I mimetic peptide/phospholipid complexes against aortic plaque burden in Watanabeheritable hyperlipidemic rabbits. Atherosclerosis. 2011;218:300-307.
22. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292-2300.
23. Nicholls SJ, Tuzcu EM, Sipahi I, Schoenhagen P, Crowe T, Kapadia S, Nissen SE. Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano. J Am Coll Cardiol. 2006;47:992- 997.
24. Navab M, Anantharamaiah GM, Hama S, Garber DW, Chaddha M, Hough G, Lallone R, Fogelman AM. Oral administration of an apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation. 2002;105:290-292.
25. Li X, Chyu KY, Faria Neto JR, Yano J, Nathwani N, Ferreira C, Dimayuga PC, Cercek B, Kaul S, Shah PK. Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation. 2004;110:1701-1705.
26. Remaley AT, Thomas F, Stonik JA, Demosky SJ, Bark SE, Neufeld EB, Bocharov AV, Vishnyakova TG, Patterson AP, Eggerman TL, Santamarina-Fojo S, Brewer HB. Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. J Lipid Res. 2003; 44:828-836.
27. Ando S, Mitsuyasu K, Soeda Y, Hidaka M, Ito Y, Matsubara K, Shindo M, Uchida Y, Aoyagi H. Structure-activity relationship of indolicidin, a Trp-rich antibacterial peptide. J Peptide Sci. 2010;16:171-177.
28. Uehara Y, Tsuboi Y, Zhang B, Miura S, Baba Y, Higuchi MA, Yamada T, Rye KA, Saku K. POPC/apoA-I discs as a potent lipoprotein modulator in Tangier disease. Atherosclerosis. 2008;197:283-289.
29. Tanigawa H, Miura S, Matsuo Y, Fujino M, Sawamura T, Saku K. Dominantnegative Lox-1 blocks homodimerization of wild-type Lox-1-induced cell proliferation through extracellular signal regulated kinase 1/2 activation. Hypertension. 2006;48:294-300.
30. Uehara Y, Miura S, von Eckardstein A, Abe S, Fujii A, Matsuo Y, Rust S, Lorkowski S, Assmann G, Yamada T, Saku K. Unsaturated fatty acids suppress the expression of the ATP-binding cassette transporter G1 (ABCG1) and ABCA1 genes via an LXR/RXR responsive element. Atherosclerosis. 2007;191: 11-21.
31. Uehara Y, Engel T, Li Z, Goepfert C, Rust S, Zhou X, Langer C, Schachtrup C, Wiekowski J, Lorkowski S, Assmann G, von Eckardstein A. Polyunsaturate fatty acids and acetoacetate downregulate the expression of the ATP-binding cassette transporter A1. Diabetes. 2002;51:2922-2928.
32. Datta G, Epand RF, Epand RM, Chaddha M, Kirksey MA, Garber DW, Lund-Katz S, Phillips MC, Hama S, Navab M, Fogelman AM, Palgunachari MN, Segrest JP, Anantharamaiah GM. Aromatic residue position on the nonpolar face of class a amphipathic helical peptides determines biological activity. J Biol Chem. 2004;279:26509-26517.
33. Kido T, Kurata H, Matsumoto A, Tobiyama R, Musha T, Hayashi K, Tamai S, Utsunomiya K, Tajima N, Fidge N, Itakura H, Kondo K. Lipoprotein analysis using agarose gel electrophoresis and differential staining of lipids. J Atheroscler Thromb. 2001;8:7-13.
34. Usui S, Nakamura M, Jitsukata K, Nara M, Hosaki S, Okazaki M. Assessment of between-instrument variations in a HPLC method for serum lipoproteins and its traceability to reference methods for total cholesterol and HDL-cholesterol. Clin Chem. 2000;46:63-72.
35. Gotsman I, Grabie N, Gupta R, Dacosta R, MacConmara M, Lederer J, Sukhova G, Witztum JL, Sharpe AH, Lichtman AH. Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation. 2006;114:2047-2055.
36. Wang N, Silver DL, Costet P, Tall AR. Specific binding of apoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1. J Biol Chem. 2000;275:33053-33058.
37. Mendez AJ, Lin G, Wade DP, Lawn RM, Oram JF. Membrane lipid domains distinct from cholesterol/sphingomyelin-rich rafts are involved in the ABCA1-mediated lipid secretory pathway. J Biol Chem. 2001;276:3158- 3166.
38. Remaley AT, Stonik JA, Demosky SJ, Neufeld EB, Bocharov AV, Vishnyakova TG, Eggerman TL, Patterson AP, Duverger NJ, Santamarina-Fojo S, Brewer HB Jr. Apolipoprotein specificity for lipid efflux by the human ABCAI transporter. Biochem Biophys Res Commun. 2001;280:818-823.
39. Smith JD, Waelde C, Horwitz A, Zheng P. Evaluation of the role of phosphatidylserine translocase activity in ABCA1-mediated lipid efflux. J Biol Chem. 2002;277:17797-17803.
40. Chroni A, Liu T, Gorshkova I, Kan HY, Uehara Y, Von Eckardstein A, Zannis VI. The central helices of apoA-I can promote ATP-binding cassette transporter A1 (ABCA1)-mediated lipid efflux. Amino acid residues 220-231 of the wild-type apoA-I are required for lipid efflux in vitro and high density lipoprotein formation in vivo. J Biol Chem. 2003;278:6719-6730.
41. Natarajan P, Forte TM, Chu B, Phillips MC, Oram JF, Bielicki JK. Identification of an apolipoprotein A-I structural element that mediates cellular cholesterol efflux and stabilizes ATP binding cassette transporter A1. J Biol Chem. 2004;279:24044-24052.
42. Fredrickson DS. The inheritance of high density lipoprotein deficiency (Tangier disease). J Clin Invest. 1964;43:228-236.
43. Shah PK. Evolving concepts on benefits and risks associated with therapeutic strategies to raise HDL. Curr Opin Cardiol. 2010;25:603-608.
44. Heinecke JW. The protein cargo of HDL: implications for vascular wall biology and therapeutics. J Clin Lipidol. 2010;4:371-375.
45. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127-135.
46. Chetiveaux M, Ouguerram K, Zair Y, Maugere P, Falconi I, Nazih H, Krempf M. New model for kinetic studies of HDL metabolism in humans. Eur J Clin Invest. 2004;34:262-267.